28.68

0.74% -0.205

Harmony Biosciences Holdings Inc (HRMY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HRMY? Forum Prognose

Schlusskurs vom Vortag:

$28.89

Offen:

$28.75

24-Stunden-Volumen:

7,930

Relative Volume:

0.01

Marktkapitalisierung:

$1.66B

Einnahmen:

$868.45M

Nettoeinkommen (Verlust:

$158.69M

KGV:

10.59

EPS:

2.7087

Netto-Cashflow:

$328.64M

1W Leistung:

+3.48%

1M Leistung:

+3.86%

6M Leistung:

+8.78%

1J Leistung:

-1.70%

1-Tages-Spanne:

$28.70

$28.76

1-Wochen-Bereich:

$27.27

$29.50

52-Wochen-Spanne:

$25.52

$40.87

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Firmenname

Harmony Biosciences Holdings Inc

Sektor

Healthcare (1108)

Branche

Biotechnology (623)

Telefon

(484) 539-9800

Adresse

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Mitarbeiter

293

Twitter

Nächster Verdiensttermin

2024-10-29

Neueste SEC-Einreichungen

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HRMY Harmony Biosciences Holdings Inc	28.71	1.67B	868.45M	158.69M	328.64M	2.7087
VRTX Vertex Pharmaceuticals Inc	436.05	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	750.33	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	800.13	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.19	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	310.52	34.37B	5.36B	287.73M	924.18M	2.5229

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-23	Herabstufung	Deutsche Bank	Buy → Hold
2026-02-23	Herabstufung	Truist	Buy → Hold
2026-02-11	Fortgesetzt	UBS	Neutral
2025-07-21	Eingeleitet	Truist	Buy
2025-07-10	Fortgesetzt	Goldman	Neutral
2025-06-02	Fortgesetzt	Oppenheimer	Outperform
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-12-17	Eingeleitet	H.C. Wainwright	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-09-10	Eingeleitet	UBS	Buy
2024-06-21	Eingeleitet	Citigroup	Buy
2024-01-02	Herabstufung	BofA Securities	Neutral → Underperform
2023-09-25	Herabstufung	Goldman	Neutral → Sell
2023-09-07	Eingeleitet	Berenberg	Buy
2023-04-20	Eingeleitet	BofA Securities	Neutral
2022-10-14	Hochstufung	Janney	Neutral → Buy
2022-10-14	Hochstufung	Jefferies	Hold → Buy
2022-08-03	Herabstufung	Jefferies	Buy → Hold
2022-07-13	Herabstufung	Goldman	Buy → Neutral
2022-07-07	Eingeleitet	Mizuho	Buy
2022-04-14	Eingeleitet	Cantor Fitzgerald	Overweight
2021-12-01	Eingeleitet	Oppenheimer	Outperform
2021-11-04	Eingeleitet	Raymond James	Outperform
2021-09-23	Eingeleitet	Needham	Buy
2021-03-29	Hochstufung	Goldman	Neutral → Buy
2020-09-14	Eingeleitet	Goldman	Neutral
2020-09-14	Eingeleitet	Jefferies	Buy
2020-09-14	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten

01:20 AM

Will Harmony’s New COO and Board Reboot Change Harmony Biosciences Holdings' (HRMY) Narrative? - simplywall.st

01:20 AM

01:18 AM

Analyst Upgrade: Can Harmony Biosciences Holdings Inc lead its sector in growthWeekly Earnings Recap & Weekly Market Pulse Updates - baoquankhu1.vn

01:18 AM

01:07 AM

Harmony Biosciences appoints COO, updates board membership - MSN

01:07 AM

Apr 11, 2026

Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? - MSN

Apr 11, 2026

Apr 10, 2026

Harmony Biosciences to Present at Needham Healthcare Conference - MyChesCo

Apr 10, 2026

(HRMY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Apr 10, 2026

Can Harmony Biosciences Holdings Inc reach all time highs this yearRate Hike & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Harmony Biosciences (HRMY) CCO RSUs Vest; 3,173 Shares Withheld for Taxes - Stock Titan

Apr 09, 2026

Apr 08, 2026